DE602005020062D1 - Lyophilisierung von virosomen - Google Patents

Lyophilisierung von virosomen

Info

Publication number
DE602005020062D1
DE602005020062D1 DE602005020062T DE602005020062T DE602005020062D1 DE 602005020062 D1 DE602005020062 D1 DE 602005020062D1 DE 602005020062 T DE602005020062 T DE 602005020062T DE 602005020062 T DE602005020062 T DE 602005020062T DE 602005020062 D1 DE602005020062 D1 DE 602005020062D1
Authority
DE
Germany
Prior art keywords
lyophilization
virusomes
virosomes
reconstitution
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020062T
Other languages
English (en)
Inventor
Rinaldo Zurbriggen
Mario Amacker
Silvia Rasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pevion Biotech Ltd
Original Assignee
Pevion Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pevion Biotech Ltd filed Critical Pevion Biotech Ltd
Publication of DE602005020062D1 publication Critical patent/DE602005020062D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE602005020062T 2004-12-30 2005-12-21 Lyophilisierung von virosomen Active DE602005020062D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04031022A EP1676569A1 (de) 2004-12-30 2004-12-30 Gefriertrocknung von Virosomen
PCT/EP2005/013829 WO2006069719A2 (en) 2004-12-30 2005-12-21 Lyophilization of virosomes

Publications (1)

Publication Number Publication Date
DE602005020062D1 true DE602005020062D1 (de) 2010-04-29

Family

ID=34928059

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020062T Active DE602005020062D1 (de) 2004-12-30 2005-12-21 Lyophilisierung von virosomen

Country Status (15)

Country Link
US (2) US20080268028A1 (de)
EP (2) EP1676569A1 (de)
CN (1) CN101119707B (de)
AT (1) ATE460923T1 (de)
AU (1) AU2005321496B2 (de)
BR (1) BRPI0519312A2 (de)
CA (1) CA2592437C (de)
DE (1) DE602005020062D1 (de)
DK (1) DK1833465T3 (de)
EA (1) EA011881B1 (de)
ES (1) ES2338908T3 (de)
PL (1) PL1833465T3 (de)
PT (1) PT1833465E (de)
WO (1) WO2006069719A2 (de)
ZA (2) ZA200701577B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2185191T3 (pl) * 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
EP3016679B1 (de) * 2013-07-02 2019-03-27 Janssen Vaccines & Prevention B.V. Verfahren zur herstellung von virosomen
EA030733B1 (ru) * 2013-12-19 2018-09-28 Янссен Вэксинс Энд Превеншн Б.В. Жидкая композиция для сохранения виросом и способ сохранения виросом
CA3013922A1 (en) * 2016-02-08 2017-08-17 The Johns Hopkins University Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof
US11160881B2 (en) 2017-04-27 2021-11-02 The Johns Hopkins University Dendrimer compositions for use in angiography
CN107375920B (zh) * 2017-06-23 2020-08-11 中农威特生物科技股份有限公司 一种猪繁殖与呼吸综合症病毒-猪流感病毒重构病毒体疫苗及其制备方法和用途
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
AU2019302562A1 (en) * 2018-07-10 2021-01-14 Seqirus Pty Ltd Removal of agglomerates
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound

Also Published As

Publication number Publication date
EA200701306A1 (ru) 2007-12-28
DK1833465T3 (da) 2010-05-31
EP1676569A1 (de) 2006-07-05
PL1833465T3 (pl) 2010-08-31
PT1833465E (pt) 2010-04-08
AU2005321496B2 (en) 2010-09-16
WO2006069719A2 (en) 2006-07-06
CA2592437C (en) 2013-06-18
ATE460923T1 (de) 2010-04-15
CN101119707B (zh) 2011-06-15
EA011881B1 (ru) 2009-06-30
WO2006069719A3 (en) 2006-10-19
ZA200701577B (en) 2008-10-29
US20080268028A1 (en) 2008-10-30
AU2005321496A1 (en) 2006-07-06
CN101119707A (zh) 2008-02-06
EP1833465A2 (de) 2007-09-19
CA2592437A1 (en) 2006-07-06
BRPI0519312A2 (pt) 2009-01-06
ES2338908T3 (es) 2010-05-13
ZA200705177B (en) 2008-10-29
EP1833465B1 (de) 2010-03-17
US20140072616A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
ATE460923T1 (de) Lyophilisierung von virosomen
EA200700702A1 (ru) Аналоги локсапина и способы их применения
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
CY1116828T1 (el) Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα
ATE471324T1 (de) Triazolophthalazine
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO345046B1 (no) Oral doseringsform
CR20130455A (es) Composiciones para el tratamiento de tumores
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1111489T1 (el) Ενωσεις για την αναστολη του πρωτεασωματος
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200700965A1 (ru) Трегалоза и/или изомальтулоза в качестве носителя для сухой ароматической композиции
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE486931T1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
EA200401032A1 (ru) Антиинфарктные молекулы
ATE425212T1 (de) Tocopherolzusammensetzungen und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition